Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE.

Journal Information

Full Title: Ther Adv Neurol Disord

Abbreviation: Ther Adv Neurol Disord

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Clinical Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Raymond Hupperts has received compensation for consulting, advisory boards and research grants and as a speaker for lectures from Biogen, and Merck.: Claudio Gasperini has received compensation for consulting from Bayer HealthCare and Biogen and as a speaker for lectures from Biogen, Bayer HealthCare, Genzyme, Merck Serono, Novartis and Teva.: Jan Lycke has received travel support and/or lecture honoraria from Biogen, Novartis, Merck, Alexion, Roche and Sanofi Genzyme; has served on scientific advisory boards for Biogen, Novartis, Merck, Roche, BSM and Sanofi Genzyme; serves on the editorial board of the Acta Neurologica Scandinavica; and has received unconditional research grants from Biogen and Novartis.: Tjalf Ziemssen has received compensation for advisory boards, trial steering committees and data and safety monitoring committees, and speaker fees and project support, from Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, and Teva.: Peter Feys has received advisory board fees for Biogen and Novartis, speaker fees from Excemed, and is an editorial board member for Multiple Sclerosis Journal and Neurorehabilitation and Neural Repair.: Jeremy Hobart has received consulting/advisor fees, honoraria, and research support from Acorda, Biogen, Genzyme, Global Blood Therapeutics, Merck Serono, Novartis, Tigercat, and Vanita.: Shan Xiao was an employee of and held stock/stock options in Biogen at the time the research was conducted. Carlos Acosta and Thijs Koster are employees of and hold stock/stock options in Biogen."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the MOBILE and ENHANCE studies and this integrated analysis were funded by Biogen."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025